J.P. Morgan Notebook Day 4: CRISPR's Not Worried; Theratechnologies' HIV Niche; And Is Moderna's IPO Coming Soon?
Daily round-up of news and notes from the 2018 J.P. Morgan Healthcare Conference: Alder's Options for CGRP drug; CRISPR's not worried about Cas9 controversy; Theratechnologies seeks more HIV niche products; Moderna is shaping up to have a big 2018; TG Therapeutics and Immunomedics milestones ahead.
You may also be interested in...
As participants from this year’s J.P. Morgan Healthcare conference recover from the torrent of new information they were exposed to, Scrip explores which biotechs saw a sustainable shift in their valuations.
Alder ended a patent dispute with Teva with a deal that will enable it to take its Phase III migraine candidate forward, while Sanofi restructures pair of partnerships with Alnylam and Regeneron heading into the J.P. Morgan Healthcare conference – where despite a flow of mid-stage deals, stakeholders are hoping US tax reform means bigger deals to come.
Approval of a transformational new product for the company could come sooner than expected after 48-week data from its pivotal study support long-term efficacy of its anti-HIV monoclonal antibody in advanced patients.